Our top pick for
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
|52-week range||$0.045 - $0.495|
|50-day moving average||$0.3436|
|200-day moving average||$0.2786|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.004|
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2021-09-09)||20.78%|
|1 month (2021-08-19)||57.63%|
|3 months (2021-06-18)||29.17%|
|6 months (2021-03-19)||287.50%|
|1 year (2020-09-18)||910.87%|
|2 years (2019-09-19)||1,921.74%|
|3 years (2018-09-19)||2,114.29%|
|5 years (2016-09-19)||5,786.08%|
|Revenue TTM||$7.2 million|
|Gross profit TTM||$7.2 million|
|Return on assets TTM||-16.82%|
|Return on equity TTM||-29.57%|
|Market capitalisation||$2.5 billion|
TTM: trailing 12 months
We're not expecting Imugene to pay a dividend over the next 12 months.
Imugene 's shares were split on a 1:7 basis on 11 November 2002. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Imugene shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Imugene shares which in turn could have impacted Imugene 's share price.
Over the last 12 months, Imugene 's shares have ranged in value from as little as $0.045 up to $0.495. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Imugene 's is 2.2543. This would suggest that Imugene 's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
Shares in the telecoms operator have jumped nearly 40% over the last 12 months.
This guide will show you step-by-step instructions on how to buy the IRON Titanium Token (TITAN) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Wabi (WABI) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Cindicator (CND) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the MonaCoin (MONA) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Bluzelle (BLZ) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Whitecoin (XWC) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Storj (STORJ) token as well as a list of exchanges you can trade it on.
Despite the good news, Qantas shares closed flat following the announcement, but that could change in the coming weeks.
Shares in the lithium producer are up five-fold over the last 12 months.
finder.com.au is one of Australia's leading comparison websites. We compare from a wide set of banks, insurers and product issuers. We value our editorial independence and follow editorial guidelines.
finder.com.au has access to track details from the product issuers listed on our sites. Although we provide information on the products offered by a wide range of issuers, we don't cover every available product or service.
Please note that the information published on our site should not be construed as personal advice and does not consider your personal needs and circumstances. While our site will provide you with factual information and general advice to help you make better decisions, it isn't a substitute for professional advice. You should consider whether the products or services featured on our site are appropriate for your needs. If you're unsure about anything, seek professional advice before you apply for any product or commit to any plan.
Products marked as 'Promoted' or 'Advertisement' are prominently displayed either as a result of a commercial advertising arrangement or to highlight a particular product, provider or feature. Finder may receive remuneration from the Provider if you click on the related link, purchase or enquire about the product. Finder's decision to show a 'promoted' product is neither a recommendation that the product is appropriate for you nor an indication that the product is the best in its category. We encourage you to use the tools and information we provide to compare your options.
Where our site links to particular products or displays 'Go to site' buttons, we may receive a commission, referral fee or payment when you click on those buttons or apply for a product. You can learn more about how we make money here.
When products are grouped in a table or list, the order in which they are initially sorted may be influenced by a range of factors including price, fees and discounts; commercial partnerships; product features; and brand popularity. We provide tools so you can sort and filter these lists to highlight features that matter to you.
We try to take an open and transparent approach and provide a broad-based comparison service. However, you should be aware that while we are an independently owned service, our comparison service does not include all providers or all products available in the market.
Some product issuers may provide products or offer services through multiple brands, associated companies or different labelling arrangements. This can make it difficult for consumers to compare alternatives or identify the companies behind the products. However, we aim to provide information to enable consumers to understand these issues.
Providing or obtaining an estimated insurance quote through us does not guarantee you can get the insurance. Acceptance by insurance companies is based on things like occupation, health and lifestyle. By providing you with the ability to apply for a credit card or loan, we are not guaranteeing that your application will be approved. Your application for credit products is subject to the Provider's terms and conditions as well as their application and lending criteria.